Search

everythinglearnresearchcommunity

for

Search:↓

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

A user experienced shedding after 7 months on Fin/Min spray despite good results and no change in treatment. Other users noted similar experiences and mentioned that shedding periods can be normal.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

8 months post hair transplant, OP experiences asymmetrical shedding despite using finasteride and starting minoxidil. The doctor suggests it might correct itself or be due to transplant trauma, recommending a wait-and-see approach.

The user experienced hair loss due to defective dutasteride and is now using a regimen including dutasteride, oral and topical minoxidil, RU58841, tretinoin, and microneedling to recover hair density. They are optimistic about regaining their hair despite recent setbacks.

The user is unhappy with the results of their second hair transplant, feeling that grafts were wasted on an already transplanted hairline instead of increasing mid-scalp density. They regret stopping medications like Dutasteride, Minoxidil, and RU58841, which led to significant hair loss, and plan to restart them.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

The user has been using various hair loss treatments, including dutasteride, oral minoxidil, finasteride, RU58841, and dermarolling, but feels they may have lost hair and is considering a hair transplant. They are advised to stick to one treatment for 6-12 months to see results, as frequent changes may hinder progress.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

The conversation is about the potential of the RCH-01/Replicel hair loss treatment and its lack of updates since 2013, with the user expressing hope for its success and considering using Minoxidil, finasteride, and dermarolling in the meantime. Other treatments mentioned as promising are Breezula and Tsuji.

The user has mostly recovered hair density using finasteride, alternating oral and topical minoxidil, and occasional dermarolling, but the crown area is still struggling. Advice includes continuing treatment for up to 24 months and possibly consulting a doctor if issues persist.

After 6 months of using finasteride, minoxidil, RU58841, and microneedling, the user experienced hair regrowth but then noticed a significant shed, returning to the initial state of hair loss. Another user responded that shedding every 6-8 months is normal when using finasteride and advised to continue the treatment for thicker hair regrowth.

Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.

The conversation discusses a person's experience with hair loss treatments, including 7 months of using finasteride and minoxidil, switching to oral minoxidil, using ketoconazole shampoo, and microneedling. They notice hair regrowth more with flash photography than in regular light.

Hair loss treatments and whether or not to buy pyrilutamide, with some users recommending using RU58841, Minoxidil, and finasteride.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

A young man faces severe hair loss in his early 20s, using treatments like dutasteride and minoxidil with little success, impacting his self-esteem and relationships. He considers hair systems and therapy as potential solutions.

The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.

A 22-year-old male experienced positive hair regrowth after using oral minoxidil and finasteride for over four months, noting slight changes in hair density. He initially used topical minoxidil but switched to oral due to having pets, experiencing minimal shedding and no significant side effects after initial lethargy from finasteride.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

The user has tried various treatments for hair loss, including finasteride, dutasteride, RU58841, Pyrilutamide, and several topical growth factors, but continues to experience a receding hairline and thinning. Despite maintaining a healthy lifestyle, the user is unsure why these treatments are ineffective and seeks advice on the underlying cause.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

Rapamycin and metformin may have hair regeneration properties. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

The user initially had success with Minoxidil for hair loss but stopped due to life changes, resulting in hair loss returning. They plan to restart treatment with Minoxidil, add Nizoral, dermarolling, and supplements like saw palmetto and beta-sitosterol, while avoiding pharmaceutical drugs.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

The user experienced side effects from various hair loss treatments, including RU58841, finasteride, and dutasteride. They are uncertain about what treatment to try next.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The conversation is about organizing hair regrowth results using a standard format in a single post for easier access. Treatments mentioned include oral minoxidil, oral finasteride, and dermarolling.